Belnacasan (VX-765) supplier|cas 273404-37-8 |DC Chemicals|Supplier|Price|Buy  

Belnacasan (VX-765) supplier|cas 273404-37-8 |DC Chemicals|Supplier|Price|Buy

DC Chemicals Supply: Belnacasan (VX-765) supplier,cas 273404-37-8, Cat No. DC5080, In stock

Contact: website: www.dcchemicals.com,

sales@dcchemicals.com,order@dcchemicals.com,info@dcchemicals.com,

Tel: +86-21-61454686;Fax:+86-21-61642837；

Product name: Belnacasan (VX-765), Synonym:　VX 765; VX-765; VX765. Belnacasan, Cat No. DC5080, Cas: 273404-37-8, Chemical Name:N/A, Molecular Formula: C24H33ClN4O6, MW: 508.99

Belnacasan (VX-765),cas 273404-37-8, Purity: >98%. Best Price and quality in the market,DC Chemicals,Primary Manufacturer, confirmed by HNMR and HPLC. VX-765 is a novel Caspase-1 inhibitor with an IC 50 of 0.8nM being investigated for the treatment of epilepsy, currently being developed by Vertex.

Belnacasan, also known as VX-765, is designed to inhibit Caspase, which is an enzyme that controls the generation of two cytokines, IL-1b and IL-18. VX-765 has been shown to inhibit acute seizures in preclinical models. In addition, VX-765 has shown activity in preclinical models of chronic epilepsy. VX-765 had been dosed in over 100 patients in phase-I and phase-IIa clinical trials relating to other diseases, including a 28-day phase-IIa clinical trial in patients with psoriasis. It has completed the treatment phase of a phase-IIa clinical trial of VX-765 that enrolled approximately 75 patients with treatment-resistant epilepsy. The double-blind, randomized, placebo-controlled clinical trial was designed to evaluate the safety, tolerability and clinical activity of VX-765.